Children diagnosed with juvenile idiopathic arthritis (JIA) have triple the risk for cancer, and the findings hold for those who were never treated with biologic therapies for JIA, according to a new study.
First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs
The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
FDA approval sought for mirdametinib in NF1-PN
SpringWorks Therapeutics has initiated a new drug application for mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.
FDA approves eflornithine for pediatric patients with high-risk neuroblastoma
Each year in the United States, there are approximately 700 to 800 cases of NB, of which 90% are diagnosed before the age of 5 years. More than half of these cases are considered high-risk.
FDA expands nivolumab approval to treat adolescents with Stage IIB/C melanoma
Patients aged 12 years and up with completely resected Stage IIB/C melanoma can now be treated (adjuvant) with FDA-approved nivolumab (Opdivo; Bristol Meyers Squibb Company).
For children with leukemia or lymphoma, what does a pediatrician need to know?
An expert in pediatric hematology and oncology discusses the important role of a child’s medical home in diagnosing and treating these disorders.
Make-A-Wish celebrates World Wish Day April 29th 2023 at American Dream
Annual Walk & Roll For Wishes raises vital funds to restore hope when hope is needed most